Document is current
Any future updates will be listed below
-
Authors
Westrich, Joseph A.
Vermeer, Daniel W. https://orcid.org/0000-0002-1501-0418
Silva, Alexa
Bonney, Stephanie
Berger, Jennifer N.
Cicchini, Louis
Greer, Robert O.
Song, John I.
Raben, David
Slansky, Jill E. https://orcid.org/0000-0003-3820-1724
Lee, John H.
Spanos, William C. https://orcid.org/0000-0002-7975-1151
Pyeon, Dohun https://orcid.org/0000-0003-1970-844X
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (R01 DE026125)
U.S. Department of Health & Human Services | National Institutes of Health (T32 AI052066)
Colorado University | UC Denver | Colorado Clinical and Translational Sciences Institute
Immunology and Microbiology Pilot Award, University of Colorado Cancer Center
Marsico Fund
- License Information
-
More Information
Article History
Received: 1 February 2019
Revised: 23 May 2019
Accepted: 26 May 2019
First Online: 15 August 2019
Compliance with ethical standards
:
: DR is a consultant for Astra Zeneca and Suvica, and an advisory board member for Astra Zeneca, Merck, EMD Serono, Genentech, and Nanobiotix. A patent has been applied for by University of Colorado and Sanford Health with DP and JHL as named inventors. The patent application number is PCT/US16/58550. All other authors declare that they have no conflict of interest.
